Publique en esta revista
Información de la revista
Vol. 15. Núm. 6.
Páginas e142-e143 (Noviembre - Diciembre 2019)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
...
Vol. 15. Núm. 6.
Páginas e142-e143 (Noviembre - Diciembre 2019)
Images in Clinical Rheumatology
DOI: 10.1016/j.reuma.2017.09.004
Acceso a texto completo
[18F] FDG PET/CT may be a useful adjunct in diagnosis of eosinophilic fasciitis
[18F] FDG PET/CT puede ser un complemento útil en el diagnóstico de fasciitis eosinofílica
Visitas
...
Javier Narváeza,
Autor para correspondencia
fjnarvaez@bellvitgehospital.cat

Corresponding author.
, Pablo Juareza, Isabel Morales Ivorraa, Laura Rodriguez Belb, Jesus Rodriguez Morenoa, Montserrat Romeraa
a Department of Rheumatology, Hospital Universitario de Bellvitge-IDIBELL, Barcelona, Spain
b PET Unit, Institut de Diagnòstic per la Imatge (IDI), Hospital Universitario de Bellvitge-IDIBELL, Barcelona, Spain
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Texto completo

Eosinophilic fasciitis (EF) is a rare connective tissue disease characterized by symmetrical and painful swelling with a progressive induration and thickening of the skin and soft tissues.1 Sometimes, it presents associated with various hematological and solid malignancies.1,2

The diagnosis of EF is confirmed by histopathological examination demonstrating a thickened fascia with an inflammatory infiltration, mostly composed of lymphocytes and eosinophils. A peripheral eosinophilia is frequently present (60–90%) but is not mandatory for the EF diagnosis. At the onset, apart from histology, magnetic resonance imaging (MRI) is currently considered the ideal imaging modality for diagnosis EF.3 This technique is also useful for determining the optimal location of muscle biopsy and for follow-up purposes. The ussefulness for the diagnosis of other imaging techniques, such as [18F] FDG-PET/CT or ultrasonography, is beginning to be explored.3–5

We report a case of EF in a 72-year-old woman who presented with a 1-month history of fatigue, weight loss, and rapidly progressive induration of her lower limbs without any skin manifestations. Laboratory tests showed an elevated erythrocyte sedimentation rate and hypereosinophilia. [18F] FDG-PET/CT discarded an occult neoplasia and revealed a diffuse and symmetrical FDG uptake in the fasciae of the legs and thighs (see Fig. 1). A biopsy specimen from the right leg, in which the FDG uptake was the strongest, showed marked eosinophilic infiltration in the fascia, but not in the muscle. The clinical suspicion of EF was confirmed and the patient was treated successfully with corticosteroids and methotrexate.

Fig. 1.

FDG-PET/CT revealed a diffuse and symmetrical FDG uptake in the fasciae of the lower limbs, clearly illustrating the anatomical involvement of the disease.

(0,39MB).

The association of malignancy with certain rheumatic syndromes, including FE was convincingly established.1,2 In those cases in which this possibility arises (explosive onset in advanced age or EF poorly responsive to corticosteroid therapy),6 the realization of a PET–CT could be useful to rule out occult neoplasia and to reinforce the suspected diagnosis.

Ethics approval

In accordance with the guidelines of our institutional ethics committee, formal approval for this study was not required. The local ethics committee agreed that the findings in this report were based on normal clinical practice and were therefore suitable for dissemination. Informed consent of the patient was obtained, and her clinical record and information were anonymized. This study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference for Harmonization.

Data availability statement

All relevant data are within the paper.

Ethical disclosuresProtection of human and animal subjects

The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data

The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent

The authors declare that no patient data appear in this article.

Funding

The authors have no support or funding to report.

Conflict of interest

The authors have declared that no competing interests exists.

References
[1]
I. Pinal Fernández, A. Selva-O’Callaghan, J.M. Grau.
Diagnosis and classification of eosinophilic fasciitis.
Autoimmun Rev, 13 (2014), pp. 379-382
[2]
H. Haddad, S. Sundaram, C. Magro, U. Gergis.
Eosinophilic fasciitis as a paraneoplastic syndrome, a case report and review of the literature.
Hematol Oncol Stem Cell Ther, 7 (2014), pp. 90-92
[3]
F. Dybowski, E. Neuen-Jacob, J. Braun.
Eosinophilic fasciitis and myositis: use of imaging modalities for diagnosis and monitoring.
Ann Rheum Dis, 67 (2008), pp. 572-574
[4]
H.J. Kim, S.W. Lee, G.J. Kim, J.H. Lee.
Usefulness of FDG PET/CT in the diagnosis of eosinophilic fasciitis.
Clin Nucl Med, 39 (2014), pp. 801-802
[5]
R. Kurimoto, K. Ikeda, D. Daiki Nakagomi, et al.
Eosinophilic fasciitis illustrated by [18F] FDG-PET/CT.
Intern Med, 55 (2016), pp. 2321-2322
[6]
J.E. Naschitz, I. Rosner, M. Rozenbaum, et al.
Rheumatic syndromes: clues to occult neoplasia.
Semin Arthritis Rheum, 29 (1999), pp. 43-55
Copyright © 2017. Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología
Idiomas
Reumatología Clínica

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.